SAN DIEGO, CA – Mindera Corporation announced that it has been selected as a finalist in the Terra2 Solutions Skin Heath Innovation Conference at the Winter Clinical Dermatology Conference. Mindera will be presenting Mind.Px, its flagship Precision Medicine test for predicting patient response to psoriasis biologics. The competition highlights companies that have developed new technologies and emerging solutions in dermatology, and will be judged by a panel of experts and conference attendees.
“We are proud to have been chosen as a finalist in the competition,” said George Mahaffey, CEO of Mindera. “Our platform opens up the exciting field of Precision Medicine to dermatology, and we are looking forward to sharing this leap forward in technology with the many future thought leaders and decision makers in dermatology clinics across the country.”
Using Mindera’s proprietary FDA Registered dermal biomarker patch, the Mindera platform allows for minimally invasive extraction of rich biomarker data from individual patient skin. Captured molecules are sent to the Mindera CLIA-certified lab for analysis. Using Machine Learning, these baseline biomarkers can be correlated to clinical outcomes data from psoriasis patients who received specific biologic drugs, resulting in continuous evolving and improving predictive analyses for personalized drug responses. Systemwide, predicting biologic responses using Mind.Px can result in both improved psoriasis patient outcomes and billions of dollars of annual cost avoidance to the healthcare system.
Mindera is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, Next-Generation Sequencing (NGS) and Machine Learning, Mindera technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera is a CLIA certified Laboratory. Find out more at www.minderadx.com.